Second implant of NTCELL for Parkinson’s

THE ROADHOUSE PHARMACY: Living Cell Technologies (ASX: LCT) announced that a second patient has been successfully implanted at Auckland City Hospital in the clinical trial of the company’s regenerative cell therapy NTCELL® for Parkinson’s disease.

LCT said it expects to complete the patient treatment phase of the study this year.

The company explained the Phase I/IIa clinical trial is an open-label investigation of the safety and clinical effects of NTCELL in patients who can no longer respond to current therapy.

“A great deal of hard work, preclinical research and scientific endeavour has gone into the discovery and development of NTCELL,” Living Cell Technologies CEO Dr Ken Taylor said in the company’s announcement to the Australian Securities Exchange.

“Our innovative approach is the first to target regeneration of brain cells for patients who are failing the current conventional treatment for Parkinson’s disease.”

The trial is under the direction of Dr Barry Snow MBChB, FRACP, FRCPC, an internationally recognised clinician and researcher in Parkinson’s disease who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board.

Website: www.lctglobal.com